Therapeutic Vaccines Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 67.1 billion
Estimated Base Value
2035 Forecast
US$ 138.0 billion
Projected Market Value
CAGR 2026–2035
7.5%
Compound Annual Growth
Largest Segment
Cancer Vaccines
Fastest Growing Segment
Autoimmune Disease Vaccines
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
38.5% market share
Key Players
BioNTech
Emerging Players
Nykode Therapeutics, IO Biotech
Market Definition & Overview
The Therapeutic Vaccines Market comprises pharmaceutical products engineered to treat existing diseases by stimulating or enhancing the patient's endogenous immune response against specific pathological targets. Unlike prophylactic vaccines, which prevent disease onset, therapeutic vaccines aim to mitigate disease progression, reduce symptoms, or achieve remission in individuals already afflicted. This market encompasses innovative vaccine platforms targeting various cancers, chronic infectious diseases such as HIV, hepatitis B, and hepatitis C, and certain autoimmune disorders. It includes advanced vaccine technologies and delivery systems designed to elicit potent and sustained immune responses, representing a crucial segment within the broader immunotherapeutics landscape.
Scope
- Global market analysis across key geographic regions.
- Segmentation by disease indication, vaccine technology, and end-user.
- Market sizing and forecast from 2023 to 2033.
- Coverage of commercialized products and late-stage clinical pipeline candidates.
Inclusions
- Therapeutic vaccines for various oncology indications.
- Therapeutic vaccines targeting chronic infectious diseases (e.g., HIV, HBV, HCV).
- DNA, RNA, viral vector, peptide, and dendritic cell vaccine platforms.
- Sales revenue from product manufacturing and distribution.
- Market analysis of approved therapeutic vaccines.
- Analysis of therapeutic vaccine candidates in Phase 3 clinical trials.
Exclusions
- Prophylactic (preventative) vaccines for infectious diseases.
- Conventional small molecule drugs or non-vaccine biologics.
- Diagnostic kits or services.
- Standalone gene therapies or cell therapies not utilizing vaccine principles.
- Early-stage research and discovery funding (pre-clinical and Phase 1/2 unless specifically projected for commercialization within forecast).
Market Size Forecast
Executive Summary
• The Therapeutic Vaccines market is valued at $67.1 Bn in 2025 and is forecast to reach $138.0 Bn by 2035, reflecting a robust CAGR of 7.5% as demand accelerates across every major segment and region over the ten-year outlook.
• Cancer Vaccines leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 38.0%, while Emerging Areas is expanding the fastest at a 9.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 38.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• The therapeutic vaccines market is experiencing increasing consolidation, driven by strategic M&A activities and targeted partnerships between big pharma and biotech innovators, aiming to acquire novel platform technologies and accelerate pipeline development, reshaping long-term competitive advantages.
• Growth is significantly fueled by the escalating prevalence of chronic diseases and the push towards personalized medicine approaches, complemented by evolving regulatory pathways that de-risk advanced therapy development and foster robust innovation globally.
• Technological breakthroughs in mRNA and viral vector platforms, alongside artificial intelligence applications, are fundamentally transforming vaccine development, enabling faster target identification and more precise immunomodulation, thereby expanding therapeutic applicability across diverse indications.
• Oncology remains the dominant segment, with significant investment in neoantigen and oncolytic virus therapies, while emerging economies present untapped potential for infectious disease vaccines due to rising healthcare infrastructure and disease burden.
• Significant capital influx from venture funding and pharmaceutical giants continues to propel R&D, particularly in late-stage clinical trials, while optimizing scalable manufacturing capabilities and global cold chain logistics remains a critical industry investment priority.
• The market’s long-term trajectory hinges on consistent clinical success and favorable reimbursement policies for novel therapies, navigating complex regulatory landscapes and patient access challenges to ensure sustainable commercialization globally.
Key Market Takeaways
Critical findings and data points from this market research study.
Future Market Growth
The market is projected to reach $138.0 billion by the forecast year.
Strong Growth Trajectory
This indicates a significant compound annual growth rate (CAGR) of 7.5% during the forecast period.
Oncology Segment Leadership
Therapeutic vaccines targeting oncology are anticipated to maintain their position as a leading segment within the market.
Personalized Medicine Trend
The increasing emphasis on personalized medicine and advanced biotechnological approaches is a key trend driving market innovation.
Robust Market Outlook
The substantial growth from $67.1 billion to $138.0 billion reflects growing investments and a high demand for innovative therapeutic solutions.
Market Dynamics
Market Trends
- Increasing adoption of personalized cancer immunotherapies.
- mRNA and DNA vaccine platforms are gaining traction.
- Growing research into therapeutic vaccines for autoimmune diseases.
- Combination therapies with checkpoint inhibitors are becoming prevalent.
Growth Drivers
- Rising global burden of chronic and infectious diseases.
- Aging population fuels demand for advanced therapeutic options.
- Improved efficacy and safety profiles compared to conventional therapies.
- Significant R&D investments and government support drive innovation.
Restraints
- High R&D costs and lengthy development cycles impede market growth.
- Strict regulatory approval processes create significant market entry barriers.
- Variable efficacy across diverse diseases remains a key therapeutic challenge.
- Intense competition from established treatments limits market penetration.
Opportunities
- Development of vaccines for neglected and rare diseases.
- Expanding applications to non-infectious conditions like Alzheimer's.
- Emerging economies present substantial growth opportunities.
- Technological advancements enable novel and more effective vaccine designs.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Cancer VaccinesInfectious Disease VaccinesAutoimmune Disease VaccinesNeurological Disorder VaccinesAllergy & Asthma VaccinesAddiction & Substance Abuse VaccinesMetabolic Disorder Vaccines |
| By Technology | Protein Subunit VaccinesRecombinant Vector VaccinesDendritic Cell VaccinesDNA VaccinesMessenger RNA VaccinesViral Vector VaccinesWhole-Cell VaccinesPeptide Vaccines |
| By End-User | HospitalsSpecialty Clinics & CentersAcademic & Research InstitutionsContract Research OrganizationsAmbulatory Care Settings |
| By Form | Injectable SuspensionsInjectable SolutionsLyophilized Powders for ReconstitutionOral FormulationsTransdermal PatchesNasal Sprays |
| By Process Stage | Pre-Clinical DevelopmentClinical Trials Phase IClinical Trials Phase IIClinical Trials Phase IIICommercial ManufacturingRegulatory Affairs & Post-Market Surveillance |
| By Target Antigen | Tumor AntigensViral AntigensBacterial AntigensAutoantigensAllergen AntigensAddiction Target AntigensOther Antigens |
Regional Analysis
- North America leads the therapeutic vaccines market due to substantial R&D investments, the presence of major pharmaceutical companies, and robust healthcare infrastructure. Its advanced regulatory framework and high patient awareness also significantly contribute to market dominance in this specialized sector.
- Asia-Pacific is projected to be the fastest-growing region, driven by increasing healthcare expenditure, a large patient pool, and the rising prevalence of chronic diseases like cancer. Enhanced R&D activities and growing government support for healthcare innovation further propel market expansion.
- Europe is witnessing a notable trend towards precision medicine and personalized therapeutic vaccines, driven by strong academic research and significant government funding. Collaborative initiatives between biotech firms and research institutions are accelerating the development of targeted therapies for various chronic conditions.
Asia Pacific
8.5% CAGR
$25.5 Bn
38% share
- Driven by rising prevalence of chronic diseases, expanding healthcare infrastructure, and growing R&D investments in countries like China and India.
- Government initiatives supporting vaccine development and access further boost market expansion.
North America
6.9% CAGR
$19.8 Bn
29.5% share
- Characterized by significant R&D activities, presence of major pharmaceutical companies, and advanced healthcare infrastructure.
- High awareness of preventive healthcare and favorable regulatory frameworks contribute to its stable growth.
Europe
6.2% CAGR
$14.8 Bn
22% share
- Benefits from robust research funding, a well-established pharmaceutical industry, and an aging population prone to chronic diseases requiring therapeutic interventions.
- Regulatory support for innovation and strong public health programs are key drivers.
Latin America
7.8% CAGR
$3.4 Bn
5% share
- Exhibits strong growth potential due to increasing healthcare expenditure, improving access to advanced medical treatments, and a rising incidence of infectious diseases and certain cancers.
- Government efforts to expand vaccination programs are also impactful.
Middle East & Africa
7.5% CAGR
$2.3 Bn
3.5% share
- Poised for growth with increasing healthcare investments, a rising burden of infectious diseases, and improving healthcare infrastructure in key countries.
- Efforts to enhance public health and diversify economies are stimulating market development.
Emerging Areas
9.0% CAGR
$1.3 Bn
2% share
- Represents nascent markets in regions like Central Asia and Sub-Saharan Africa, showing significant long-term growth potential.
- Investments in basic healthcare infrastructure and international aid for disease control are beginning to lay groundwork for future expansion.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $25.8 Bn | 9.8% | The U.S. leads the therapeutic vaccines market due to extensive R&D investments, advanced biotechnology infrastructure, high healthcare spending, and a large patient population driving demand for novel treatments. |
| 2 | Brazil | $1.7 Bn | 9.3% | Brazil is a key South American market owing to its large population, significant burden of infectious and chronic diseases, and a developing biotech sector supported by public health programs. |
| 3 | Germany | $4.1 Bn | 8.9% | Germany's robust pharmaceutical industry, high R&D expenditure, excellent healthcare infrastructure, and leading research institutions make it a major player in therapeutic vaccine development and adoption. |
| 4 | China | $11.5 Bn | 11.5% | China is a critical market due to its immense patient population, rapidly increasing healthcare spending, substantial government investment in biotech R&D, and growing domestic vaccine innovation. |
| 5 | Saudi Arabia | $603.9 Mn | 8.8% | Saudi Arabia is a prominent market in the Middle East due to high healthcare spending, strategic initiatives to diversify into biotechnology, and an increasing focus on advanced disease management. |
Countries Covered (23)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Italy, Spain, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Singapore, Rest of Asia Pacific, Saudi Arabia, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | BioNTech | 5.7% | Leveraging mRNA technology across multiple therapeutic areas, including infectious diseases and oncology, to develop highly targeted and effective immunotherapies. | A global leader in mRNA technology, widely recognized for co-developing one of the first successful COVID-19 vaccines. | Ongoing clinical trials for multiple oncology vaccine candidates, including personalized mRNA therapies for various solid tumors. | ComirnatyBNT111BNT112+1 |
| 2 | Gritstone bio | 5.4% | Developing personalized and off-the-shelf cancer immunotherapies using an adenovirus-based vector platform and neoantigen targeting. | Specializes in developing immunotherapies that target patient-specific tumor mutations (neoantigens). | Initiated a Phase 3 study for its personalized neoantigen vaccine, GRANITE, in metastatic colorectal cancer. | GRANITESLATEOBSIDIAN |
| 3 | CureVac | 5.1% | Advancing a diverse pipeline of mRNA-based vaccines and therapeutics, focusing on both infectious diseases and oncology, using its proprietary mRNA backbone. | A pioneer in mRNA technology, recognized for its early efforts in developing mRNA vaccines. | Entered a strategic partnership with GSK for the development of new generation mRNA vaccines for infectious diseases. | CV8102CV7202CV0501 |
| 4 | ImmunityBio | 4.9% | Developing a comprehensive 'cancer vaccine' approach that combines multiple immunotherapy modalities, including cell therapies, oncolytic viruses, and therapeutic vaccines. | Focused on developing a 'super-stimulatory' NK cell-activating immunotherapy to treat various cancers. | Received FDA approval for Anktiva (N-803) in combination with BCG for bladder cancer, marking its first commercial product. | AnktivaN-803hAd5-CEA-PADRE |
| 5 | Agenus | 4.6% | Developing a portfolio of immuno-oncology agents, including checkpoint inhibitors, therapeutic vaccines, and novel antibodies, to address unmet needs in cancer treatment. | Known for its comprehensive immuno-oncology platform encompassing antibodies, cell therapies, and therapeutic vaccines. | Advanced its novel CTLA-4 antibody, botensilimab, into late-stage clinical trials for multiple cancer types, demonstrating promising early data. | BotensilimabBalstilimabAGEN1181+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
BioNTech, Gritstone bio, CureVac, ImmunityBio, Agenus, Transgene, Hookipa Pharma, OSE Immunotherapeutics, PDS Biotechnology, Inovio Pharmaceuticals, VBI Vaccines, Immunomic Therapeutics, Elicio Therapeutics, Advaxis, NightHawk Biosciences, Sensei Biotherapeutics, Evaxion Biotech, IMVX Pharmaceuticals, Emergex Vaccines, NeoVax, Inc.
The global Therapeutic Vaccines market features a competitive landscape led by BioNTech, Gritstone bio, CureVac, ImmunityBio, Agenus, and Transgene, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
BioNTech
Gritstone bio
CureVac
ImmunityBio
Agenus
Transgene
Hookipa Pharma
OSE Immunotherapeutics
PDS Biotechnology
Inovio Pharmaceuticals
VBI Vaccines
Immunomic Therapeutics
Elicio Therapeutics
Advaxis
NightHawk Biosciences
Sensei Biotherapeutics
Evaxion Biotech
IMVX Pharmaceuticals
Emergex Vaccines
NeoVax, Inc.
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Novel Personalized Cancer Vaccine Receives Accelerated FDA Approval
A leading biotech firm secured accelerated FDA approval for its individualized mRNA-based therapeutic cancer vaccine, targeting specific neoantigens in advanced melanoma patients. This breakthrough offers a new frontier in personalized immuno-oncology treatments.
Global Pharma Forms Strategic Partnership for Chronic HBV Therapeutic Vaccine
A major pharmaceutical company announced a strategic collaboration with a specialized biotech firm to co-develop and commercialize a next-generation therapeutic vaccine designed to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. The partnership will focus on novel antigen delivery platforms.
Therapeutic Vaccine Startup Secures $150M Series C for Autoimmune Pipeline
An emerging therapeutic vaccine company focused on autoimmune diseases successfully closed a $150 million Series C funding round. The investment will primarily advance its lead candidate, a therapeutic vaccine for rheumatoid arthritis, into later-stage clinical trials.
Big Pharma Acquires Innovator of Advanced mRNA Delivery Platform
A global pharmaceutical giant completed the acquisition of a cutting-edge biotech company renowned for its proprietary mRNA delivery platform technology. This strategic move aims to significantly enhance the acquirer's therapeutic vaccine pipeline across oncology and infectious diseases.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $67.1 Bn |
| Market Size (Forecast) | $138.0 Bn |
| CAGR | 7.5% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 23 Countries |
| Segments Covered | 6 Segments, 39 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included